Geert-Jan Mulder

Geert-Jan Mulder, MD, is a Managing Partner at Forbion, co-founded the fund in 2006 and currently serves on the Board of several Forbion portfolio companies. In addition, Geert-Jan led the firm’s successful investment in 2004 in bluebirdbio (NASDAQ: BLUE), which went public in 2013, where he supported the company in clinical development and served as the chairman for several years. Other investments include Acorda Therapeutics (NASDAQ:ACOR), which went public in 2006 where he was part of the AMPYRA®(dalfampridine) board panel to evaluate a new regulatory endpoint in Multiple Sclerosis; PanGenetics B.V. which sold to Abbott, where he led the Series B financing round; Transave, where supported the company’s clinical development for ARIKAYCE®(liposomal amikacin for inhalation) partly as interim CMO, he also served on the Board of Directors till the merger with Insmed (NASDAQ:INSM) in 2010; led the Series A of Exosome Diagnostics in the field of liquid biopsy in 2010 which was acquired by Bio-Techne (NASDAQ:TECH) in 2018; and Promedior, where he led the Series C financing round and participated in setting up and executing its clinical development plan, for an antifibrotic treatment of Idiopathic Lung Fibrosis (IPF) and Myelofibrosis, received Breakthrough Therapy Designation by the FDA for IPF and being phase III ready at the time of its acquisition by Roche (ROG SW) in 2020. In addition he is a co-author of several Forbion and Forbion portfolio related scientific publications.

Prior to joining ABN AMRO Capital Life Sciences (Forbion’s predecessor) in 2001, Geert-Jan spent two years as resident in OBGYN at the University Medical Center of Utrecht (UMC) and several years in the pharmaceutical industry in clinical development and global medical marketing for both Searle (now Pfizer) and Byk Gulden (now Takeda).